|Bid||15.10 x 0|
|Ask||15.60 x 0|
|Day's Range||15.00 - 15.80|
|52 Week Range||10.80 - 42.80|
|Beta (5Y Monthly)||2.22|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov. 03, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||44.25|
NEW YORK, NY / ACCESSWIRE / September 23, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (NASDAQ:PTGX).
NEW YORK, September 23, 2021--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (NASDAQ: PTGX) on behalf of Protagonist stockholders. Our investigation concerns whether Protagonist has violated the federal securities laws and/or engaged in other unlawful business practices.
RADNOR, Pa., Sept. 22, 2021 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of shareholders of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) (“Protagonist”). Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from its proprietary technology platform. Protagonist’s pipe